Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesBlend, MetabolicRetatrutide + Tirzepatide (Blend)

Retatrutide + Tirzepatide (Blend)

/ Two-component blend — retatrutide (triple GLP-1/GIP/glucagon agonist) plus tirzepatide (dual GLP-1/GIP agonist)
TIER 2 · TranslationalN = 0 · TESTING PENDING

ALIAS · SA-3R/SA-2T · Triple-agonist + dual-agonist blend

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · CLASS · Two-component blend — retatrutide (triple GLP-1/GIP/glucagon agonist) plus tirzepatide (dual GLP-1/GIP agonist)CATEGORY · Blend, Metabolic

Tier 2 by component evidence. Each component independently has Phase 3 (tirzepatide, FDA-approved) or Phase 2 (retatrutide) data. The specific combination has no published RCT — vendor sale presents this as a pharmacologically incoherent stack since both molecules engage GLP-1 receptors and there is no published rationale for dual administration.

§ B · Mechanism of action

The combination overlaps significantly at the GLP-1 and GIP receptors — both molecules engage both receptors. The unique pharmacology added by combination is glucagon receptor agonism (retatrutide-only) on top of an already-saturated GLP-1/GIP system. No published mechanistic study supports the combination as additive or synergistic over retatrutide monotherapy.

§ C · Human clinical evidence

None for the combination. Component evidence: tirzepatide Phase 3 (SURMOUNT trials) supported FDA approval for weight management; retatrutide Phase 2 (Jastreboff 2023) showed up to 24% weight loss.

§ F · Safety signal

No combined safety database. Stacking two incretin agonists — both with overlapping receptor engagement and overlapping GI adverse-event profiles — increases the dose-limiting nausea/vomiting risk without a clear pharmacological reason.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

This blend is a vendor-driven marketing construct without pharmacological justification in the published literature. Editors should be especially clear with readers that no published study supports stacking two incretin agonists with overlapping mechanism.